The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The safety and efficacy of elranatamab in patients with R/R AL amyloidosis
Pedro Vianna, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of elranatamab in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. The study found that off-label use of elranatamab led to rapid and deep hematological responses with a tolerable safety profile. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
